OBJECTIVES The aim of this study was to examine the independent associations between actionable bleeding (AB) and coronary thrombotic events (CTE) on mortality risk after percutaneous coronary intervention (PCI).
The unavoidable corollary to such therapy is bleeding, however, which also is associated with increased risk for both short-and long-term mortality (2, 4) . As a result, identifying the optimal duration of DAPT that min- Although several studies have examined such associations, some evaluated bleeding and thrombosis separately, with limited data reported after mutual adjustment for both types of events (8) (9) (10) . This is a clinically relevant distinction, as frequently observed contributors to bleeding, such as older age, renal dysfunction, and ST-segment deviation (11) , are also linked with increased risks for thrombosis (12, 13) , suggesting that many patients may be at high and comparable risk for both events. Accordingly, we sought to examine the association between both bleeding and thrombotic complications, on subsequent mortality risk in a large and contemporary cohort of patients undergoing PCI. DEFINITIONS. ST was defined according to the Academic Research Consortium criteria (15) . MI was defined in accordance with the universal definition (16) . For the present analysis, coronary thrombotic events (CTE) were defined as definite or probable ST or MI. Bleeding was classified using the Bleeding Academic Research Consortium (BARC) criteria (17) .
METHODS
We classified actionable bleeding (AB) as BARC type 2 or 3. BARC type 2 is defined as clinically overt hemorrhage requiring medical attention, whereas BARC type 3 includes bleeds with a hemoglobin decrease of at least 3 g/dl, requiring transfusion or surgical intervention. Death was classified as cardiac or noncardiac per the Academic Research Consortium definitions (15) . Our primary intent was to examine mortality risk related to nonfatal CTE and bleeding, as both of these events were either reduced or increased by a prolonged DAPT strategy (6) . As a result, we did not model associations for events that AB and with and without CTE, respectively. Analyses were repeated after excluding patients who experienced both AB and CTE over the study period (n ¼ 66).
The cumulative incidence of CTE, AB, and death at 2 years was calculated using the Kaplan-Meier method as the time to first occurrence of each adverse event. We then examined associations between CTE, AB, and death. In these analyses, allcause death at 2 years served as the dependent outcome, whereas CTE and AB represented the key independent variables of interest. As CTE and AB occur over time, we generated time-dependent covariates for these exposures, thereby allowing subjects to contribute exposure time before and after the occurrence of either adverse event. To account for the timing of CTE in relation to PCI and the different components of CTE (ST or MI), the time-dependent covariate for CTE was hierarchical, in which the most severe state was defined as nonperiprocedural ST followed by nonperiprocedural MI and then periprocedural ST or MI. Analogously, AB was entered as a hierarchical time-dependent covariate in which the highest risk state was nonperiprocedural BARC type 3 followed by nonperiprocedural BARC type 2 and then periprocedural bleeding. Hazard ratios (HR) were generated using extended Cox regression, a flexible modeling approach that allows departures from proportional hazards with covariates that either interact with or vary by time (18, 19) . Models were adjusted using the following covariates that were either significantly different between exposure groups or plausibly related to mortality: age, sex, acute coronary syndrome, stent type, region (United States Over the 2-year study period, a total of 340 patients (6.8%) were lost to follow-up. The crude incidence of CTE, AB, and all-cause mortality at 2 years is depicted in Figure 1 . associated with mortality risks of comparable magnitude, whereas nonperiprocedural BARC type 3 bleeding was associated with an approximate 2-fold higher risk compared with BARC type 2 bleeding. All other parameters with significant associations with 2-year mortality are presented in Online Table 1 .
Associations among CTE, AB, and 2-year mortality across different clinical subgroups are shown in Figure 3 . In general, both CTE and AB were associated with similar mortality hazards, without evidence of statistical interaction. As shown in Online Figure 1 , most deaths after CTE or AB occurred at least 30 days after the index event (59.0% and 72.0%). Additional sensitivity analyses after excluding patients with both CTE and AB (n ¼ 66) or using cardiac death as the dependent outcome are shown in Online Tables 2 and 3, with similar results to our primary analyses.
DISCUSSION
In the present study, comprising more than 5,000
patients undergoing PCI, we found substantial, independent, and comparable risks for mortality over We also assessed the influence of antiplatelet therapy status at the time of thrombosis or bleeding as a modifier of mortality risk related to each event.
We found that the mortality hazard associated with In addition, most deaths after AB and CTE occurred at least 30 days after the event, a time interval that
indicates that such nonfatal events may serve more as proxies or markers of risk rather than as direct and causal antecedents to mortality.
In addition to examining the impact of bleeding and CTE that occurred over the entire study period,
we also evaluated associations after taking into account the timing and severity of each respective event. Periprocedural thrombotic events were much more common than bleeding complications, occurring in 30% and 8% of patients, respectively. Moreover, early bleeding was associated with a marginally higher mortality risk compared with periprocedural CTE, consistent with prior findings by Lindsey et al. (25) . Thrombotic events were restricted to coronary thrombosis, as we did not collect follow-up information on noncoronary ischemic events. Whether a broader definition of thrombosis may modify the associations we observed, therefore, warrants further investigation. In addition, as almost all PARIS participants were treated with clopidogrel, our findings may not be generalizable to the more potent P2Y 12 antagonists prasugrel and ticagrelor.
CONCLUSIONS
We found that AB and intracoronary thrombosis were associated with substantial and comparable risks for mortality over a 2-year period after PCI. These results highlight the importance of both ischemic and hemorrhagic complications in a contemporary cohort, findings that may provide clinically relevant insight on the risk/benefit calculations for decisions regarding the extension or discontinuation of DAPT after PCI. WHAT IS NEW? In this report, we demonstrate that both nonfatal AB, defined as BARC type 2 or 3, and coronary thrombosis occurring over a 2-year period after PCI associate with all-cause mortality to a similar extent. Risk after both events was highest in the first 30 days, with attenuation thereafter.
WHAT IS NEXT? These findings support the development of stratification tools to refine long-term risk estimation for both bleeding and thrombosis after PCI.
